Case Reports in Hepatology

Case Reports in Hepatology / 2020 / Article

Case Report | Open Access

Volume 2020 |Article ID 9368348 | 6 pages |

Hepatocellular Glycogen Accumulation in the Setting of Poorly Controlled Type 1 Diabetes Mellitus: Case Report and Review of the Literature

Academic Editor: Sorabh Kapoor
Received10 Nov 2019
Accepted22 Jan 2020
Published17 Feb 2020


Glycogenic hepatopathy (GH) is the accumulation of glycogen in the hepatocytes and represents a rare complication in patients with diabetes mellitus (DM), most commonly type 1 DM. We present a case of a 23-year-old woman with a medical history of poorly controlled type 1 DM and gastroesophageal reflux disease (GERD) who presented with progressively worsening right-sided abdominal pain. Diagnostic workup resulted in a liver biopsy with hepatocytes that stained heavily for glycogen with no evidence of fibrosis or steatohepatitis. A diagnosis of glycogenic hepatopathy was made, and an aggressive glucose control regimen was implemented leading to resolution of symptoms and improvement in AST, ALT, and ALP. In addition to presenting this rare case, we offer a review of literature and draw important distinctions between glycogenic hepatopathy and other differential diagnoses with the aim of assisting providers in the diagnostic workup and treatment of glycogenic hepatopathy.

1. Introduction

Glycogenic hepatopathy, a rare occurrence usually seen in poorly controlled type 1 DM, is due to the accumulation of glycogen within the hepatocytes [1]. Patients with GH have an enlarged liver, elevated liver enzymes, and commonly present to the hospital with complaints of right upper abdominal pain [15]. It is crucial that this condition is diagnosed and differentiated from other conditions which present with similar symptoms, as GH is reversible unlike other differentials including nonalcoholic fatty liver disease (NAFLD) which is more commonly seen in type 2 DM [3]. Despite the increasing incidence of diabetes in the United States [6], the real incidence and prevalence of GH are unknown [15, 716], commonly being misdiagnosed or underdiagnosed. We present a case of a patient with poorly controlled type 1 diabetes who presented with abdominal pain, abnormal liver enzymes, and massive enlargement of the liver and was subsequently diagnosed with glycogenic hepatopathy.

2. Case Presentation

A 23-year-old woman with type 1 DM, GERD, amenorrhea (resolved) and more recently irregular menstrual periods whom presented to the emergency department with complaints of right-sided abdominal pain of 14 days duration. Pain was described as sharp in nature, intermittent, worsened by eating, and without any relieving factors. It was associated with nausea and had been progressively increasing in intensity and frequency of occurrence. She was diagnosed with type 1 DM 11 years prior, which was poorly controlled, with a mean HbA1c of 12.05% over a 2-year period. She had been admitted multiple times for DKA.

At presentation, the patient appeared well developed for her age except for a short stature and being underweight (BMI 17.54). She was tachycardic (HR 117 bpm) and tender in the right upper and lower quadrants of the abdomen without guarding or rebound tenderness. The liver was palpable 3 inches below the right costal margin. Laboratory results revealed mild DKA as evidenced by the elevated blood sugar (344 mg/dl), anion gap acidosis of 17, HCO3 of 18 mMol/L, venous pH 7.31, serum ketones < 1 : 4 dilution, and trace urine ketones. Her blood glucose reduced to 76 mg/dl after two liters of intravenous fluids. Her home insulin regimen was promptly resumed, and she did not require an insulin infusion. AST (511 mg/dl), ALT (366 mg/dl), and ALP (304 mg/dl) were elevated. Lactic acid was elevated at 8.0 mg/dL. Total bilirubin (0.4 mg/dl), albumin (4 mg/dl), INR (0.9), and platelet count (248 cells/microliter) were within normal limits. HbA1c on presentation was 11.5%. Other laboratory values including amylase and lipase were within normal limits.

Commuted tomography (CT) of the abdomen and pelvis with contrast (Figures 1 and 2) showed an enlarged liver, 26 cm in full length with mass effect on adjacent structures including the inferior vena cava, stomach, duodenum, pancreas, and hepatic flexure of the colon. Abdominal ultrasound with Doppler was negative for hepatic vein thrombosis. Of note, the patient was not on any hepatotoxic medications. Laboratory workup for causes of elevated liver enzymes including: infective workup (EBV, CMV, Hepatitis A, B, and C), iron studies (normal ferritin, decreased total iron, and iron saturation), ceruloplasmin level, serum alpha-fetoprotein, and thyroid function were all within normal limits. Celiac disease had been ruled out previously in the outpatient setting with negative tissue transglutaminase antibodies and endomysial antibody. Autoimmune workup including antinuclear antibody (ANA) titer, antismooth muscle antibody, antimitochondrial antibody, and liver/kidney microsome were all negative or within normal limits. A transthoracic echocardiogram showed normal right and left ventricular functions, with a left ventricular ejection fraction of 55–60%.

CT-guided biopsy of the liver was done due to diagnostic uncertainty and increasing AST/ALT (Table 1). Liver biopsy showed pale and swollen hepatocytes (Figure 3) with heavy glycogen staining seen on Periodic Acid Schiff (PAS) stain (Figure 4) which was absent after digestion with diastases (Figure 5). Numerous intranuclear glycogen inclusions, as well as some patchy steatosis, were noted. There were no signs of fibrosis or increased iron deposition.

Trends in liver enzymes


A diagnosis of glycogenic hepatopathy was made. She was managed symptomatically for pain and strict glycemic control was implemented. Symptoms of abdominal pain improved, and lactic acid returned to normal (1.7 mg/dl) on hospital day 3 with adequate fluid resuscitation. The patient was discharged home on hospital day 7 (Table 1) with a more aggressive insulin regimen, and follow-ups with her primary care physician (PCP) and endocrinologist were scheduled. At discharge (day 7), AST, ALT, and ALP were 237 mg/dl, 271 mg/dl, and 200 mg/dl, respectively. Unfortunately, the patient was not compliant with follow-up and was not seen for another year at which time her HbA1C was 12.6%. Liver enzymes however were within normal limits with ALT, AST, and ALP at 20 mg/dl, 35 mg/dl, and 54 mg/dl, respectively. Repeat contrasted CT abdomen twelve months later showed persistent hepatomegaly measuring 27.8 × 21.4 × 15.5 cm (Figures 6 and 7). Liver dimensions were similar to the CT findings at initial presentation. The importance of strict glycemic control was reemphasized, and she was rescheduled for follow-up with her primary care physician and endocrinologist.

3. Discussion

Glycogenic hepatopathy (GH) is the accumulation of glycogen in the hepatocytes [15, 711]. Mauriac first described a syndrome in the 1930s after observing children with brittle diabetes who had reduced growth, delayed puberty, Cushing-like features, hepatomegaly, and elevated liver enzymes [5]. Over time, children and adults with brittle diabetes were noted to present with some components of Mauriac syndrome, commonly hepatomegaly and elevated liver enzymes termed glycogenic hepatopathy [7]. GH is underrecognized and often confused with fatty liver disease and nonalcoholic steatohepatitis, which is more common in type 2 diabetes. The exact incidence and prevalence of the disease are unknown [15, 711]. Classically it is seen in longstanding, poorly controlled, type 1 diabetes (98% of cases) with a mean duration of 10.5 years and a mean HbA1c of 11.8 [13]. No gender predilection exists for developing GH [1, 4], and patients typically have a healthy body mass index [14].

The exact mechanism by which glycogen accumulates in the cytoplasm of the hepatocytes in patients with glycogenic hepatopathy is unknown. Higher glucose concentration activates the passive diffusion of glucose across the cell membrane by a noninsulin-dependent mechanism bypassing the insulin-dependent serum glucose transporter-2 (SGT-2) that acts to maintain glucose equilibrium between the extracellular and intracellular space [17]. This passive diffusion of glucose across the cell membrane by a noninsulin-dependent mechanism leads to increased glucose in the cytoplasm [17]. High levels of glucose in the cell results in more substrates for glycogen synthesis. Glucokinase present in the cytoplasm converts glucose to glucose-6-phosphate while glycogen synthetase, an enzyme also present in the cytoplasm of hepatocytes, converts glucose-6-phosphate to glycogen [8, 10]. A phosphatase activates glycogen synthase by dephosphorylation, and a high concentration of glucose and insulin modulate the activities of this phosphatase [18]. Thus, increased hepatic glycogenesis is thought to occur due to the presence of high cytoplasmic glucose concentration as well as the presence of exogenous insulin [3, 810]. The activation of phosphatase by increased cytoplasmic glucose and high levels of exogenous insulin rather than an alteration in the coding sequence of the glycogen phosphorylase gene better explain the increased activity of phosphatase seen in patients with GH [19].

Clinically, patients with GH may present in DKA with symptoms such as polyuria, polydipsia, dehydration, abdominal pain, nausea, and vomiting [18, 20]. They also have hepatomegaly (more than 90% of the time) [21], varying degree of elevated transaminases, and rarely elevated alkaline phosphatase. Elevated liver enzymes present with a hepatocellular pattern of injury rather than a cholestatic pattern [1, 2, 9], usually with AST greater than ALT [22]. This is likely due to enzyme leakage as a result of hepatocyte membrane injury [1, 19]. There is no histologic evidence to suggest cell death as a cause of elevated transaminases [22]. Hepatocellular injury in GH can present with mild elevations in transaminases to dramatically elevated values with some reported cases of liver enzymes up to 30 times the upper limit of normal [2325]. Satyarengga et al. reported a case with peak AST of 3725 mg/dl and ALT 1049 mg/dl [24]. However, no cases of acute liver failure have been reported in the literature. As seen in our patient, elevation in lactic acid can occur in these patients [16]. The exact significance of this remains unknown [26]. However, some studies attribute this to reduced gluconeogenesis and lack of conversion of pyruvate to glucose [16]. Patients with GH do not have abnormalities in the synthetic function of the liver [2, 20]. There are a few cases of GH presenting with ascites without any signs of cirrhosis. The mechanism of ascites remains unclear [1]. Other laboratory abnormalities in patients with GH include a high amylase and/or lipase in patients with no clinical or radiographic evidence of acute pancreatitis [11]. The underlying mechanism of this is also unknown [11]. However, these findings of elevated lipase and amylase were not present in our patient.

A high index of suspicion is required in a patient with poorly controlled type 1 diabetes who presents with abdominal pain, hepatomegaly, and elevated liver enzymes [21]. There are, however, case reports of GH occurring in patients with type 2 diabetes with poor glycemic control [12, 13]; nondiabetics on high dose steroids [14]; a 3-year-old with dumping syndrome associated with gastrostomy feeding without glucose intolerance [15]; a patient who developed rapid onset hyperglycemia but had a HbA1c of 6.2% [27]; and a person with type 2 diabetes who attempted suicide with large dose of insulin glargine, treated with hypercaloric infusion [13].

The diagnosis of GH is made in patients in whom we have a high index of suspicion following a comprehensive history, physical examination, laboratory testing, and imaging studies. Liver biopsy is the gold standard for making a diagnosis of GH [21] but this is not always necessary. Liver biopsy should be performed in cases where the diagnosis is not definite, and other causes of hepatic dysfunction cannot be excluded [21]. Similarly, liver biopsy is reserved for patients who do not respond to treatment with tight glycemic control or have a persistent rise in liver enzymes despite improved glycemic control [28]. In evaluating diabetic patients with abdominal pain, hepatomegaly, and elevated liver enzymes in whom we suspect GH, history should include the duration of symptoms, how long the patient has had diabetes, and level of glycemic control. Abdominal imaging including ultrasound scan (US), CT, and gradient dual echo magnetic resonance imaging (MRI) are helpful non-noninvasive tools which, in addition to history and physical examination, can aid in the diagnosis of GH and reduce the need for invasive liver biopsies [21]. Sweetser and Kraichely reported the usefulness of CT to distinguish GH from fatty liver disease [29]. CT scan can differentiate higher liver densities in GH from lower densities seen in patients with fatty liver [29]. However, the use of CT scan is limited in cases where lower liver densities associated with fatty change occur in patients with GH [27] or cases with a smaller increase in liver density than expected, as seen in glycogen storage diseases [30, 31]. The use of CT scan in diagnosing GH may further be complicated by conditions that cause the liver to be hyperdense on imaging as seen in hemochromatosis and iodine deposition in the liver of patients who take amiodarone [28, 29]. Gradient dual echo MRI can distinguish fat deposition from edematous conditions, such as patients with acute liver injury, and from hepatitis both of which may appear as low-density areas on CT [32, 33]. The sensitivity of gradient dual echo MRI combined with other imaging modalities, like abdominal US and CT, increases in differentiating between GH and NASH thus reducing the need for a liver biopsy [27]. Unfortunately, our patient did not get a gradient dual echo MRI as this is not done at our center. Due to diagnostic uncertainty in our patient’s presentation, a liver biopsy was done to confirm the diagnosis. Noninvasive tests like Fibro Sure have no use in the evaluation of GH or in differentiating GH from NASH [21]. The importance of differentiating these two clinical entities is necessary as their management and prognosis differ. All cases reported so far indicate that GH runs a benign [2, 10, 18, 19] and reversible course with tight glycemic control, while some cases of NASH progress to cirrhosis and hepatocellular carcinoma [34].

Histologically, accumulation of glycogen in the hepatocytes is pathognomonic. Hepatocytes are pale and swollen. There is absent to minimal inflammation and no fatty changes or spotty lobular necrosis. The architecture of the liver is preserved without any significant fibrosis. Glycogen accumulation demonstrated using PAS-diastase staining shows abundant cytoplasmic glycogen deposits which disappear after digestion with diastase [1, 20].

Liver enzymes usually normalize within 2–14 weeks of tight glycemic control, mostly achieved by subcutaneous insulin administration [10, 35, 36]. In two case reports, patients with poorly controlled type 1 diabetes and frequent episodes of hypoglycemia diagnosed with GH had a resolution of GH following pancreatic transplantation for other indications [19]. GH can recur if there is a relapse in poor glycemic control [9]. The level of glycemic control required for normalization of transaminitis and complete resolution of hepatomegaly remains unclear. However, few cases have reported decrease or normalization of liver enzymes and improvement of symptoms with a modest drop in HbA1c, without the need for aggressive insulin treatment [22, 29]. Cha et al. reported the resolution of transaminitis in patients with HbA1c above 11%. Similarly, Parmar et al. reported relief of abdominal pain and a decline in liver enzymes in their patient with a decrease in HbA1c of 0.6% (13.7% to 12.7%) [25].

In our patient, despite suboptimal glucose control, transaminitis resolved and liver enzymes were within normal limits a year later, which points towards the benign course of the disease. Follow-up repeat CT of the abdomen did not show a reduction in liver size which could be explained by the suboptimal glucose control, noncompliance with insulin regimen evident by HbA1c of 12.6%, and temporary loss to follow-up. The patient remains at risk for relapse due to inadequate glycemic control [9, 37].

4. Conclusion

Patients with GH usually present with nonspecific symptoms that may lead to a delay in diagnosis. In patients with type 1 DM with elevated liver enzymes with or without hepatomegaly, glycogenic hepatopathy should be considered as a differential diagnosis. A high index of suspicion by clinicians can lead to prompt diagnosis and potentially decrease the need for unnecessary testing in this patient population. It is important to distinguish GH from NAFLD for prognostication and management with the former following a benign cause and the latter progressing to cirrhosis in some cases. We advocate more research to understand better risk as well as potentiating and/or protective factors associated with the development of GH.

Conflicts of Interest

The authors declare that they have no conflicts of interest.


  1. M. Toberson, Y. Y. Chen, E. Brunt et al., “Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus,” American Journal of Surgical Pathology, vol. 30, no. 4, pp. 508–513, 2006. View at: Publisher Site | Google Scholar
  2. R. Chatila and B. A. West, “Hepatomegaly and abnormal liver tests due to glycogenosis in adults with diabetes,” Medicine, vol. 75, no. 6, pp. 327–333, 1996. View at: Publisher Site | Google Scholar
  3. A. Abaci, O. Bekem, T. Unuvar et al., “Hepatic glycogenosis: a rare cause of hepatomegaly in type 1 diabetes mellitus,” Journal of Diabetes and Its Complications, vol. 22, no. 5, pp. 325–328, 2008. View at: Publisher Site | Google Scholar
  4. G. S. Sayuk, J. E. Elwing, and M. Lisker-Melman, “Hepatic glycogenosis: an underrecognized source of abnormal liver function tests?” Digestive Diseases and Sciences, vol. 52, no. 4, pp. 936–938, 2007. View at: Publisher Site | Google Scholar
  5. P. Mauriac, “Gros ventre: hepatomegaly, troubles de las croissance chez les enfants diabetiques traits depuis plusieurs annes par l’insuline,” Gax Hebd Med Bordeaux, vol. 26, pp. 402–410, 1930. View at: Google Scholar
  6. Center for Disease Control and Prevention, National Diabetes Statistics Report, CDC, Atlanta, GA, USA, 2017.
  7. N. M. O. Zuckerman-Levin and N. Shehadeh, “Glycogenic hepatopathy in an adolescent with type 1 DM,” in Diabetes Case Studies, pp. 175–179, American Diabetes Association, Alexandria, VA, USA, 2015. View at: Google Scholar
  8. S. S. Rogal, C. Ukomadu, B. D. Levy, and J. Loscalzo, “A sweet source of abdominal pain,” New England Journal of Medicine, vol. 364, no. 18, pp. 1762–1767, 2011. View at: Publisher Site | Google Scholar
  9. S. Messeri, L. Messerini, F. Vizzutti, G. Laffi, and F. Marra, “Glycogenic hepatopathy associated with type 1 diabetes mellitus as a cause of recurrent liver damage,” Annals of Hepatology, vol. 11, no. 4, pp. 554–558, 2012. View at: Publisher Site | Google Scholar
  10. C. Munns, R. McCrossin, M. Thomsett, and J. Batch, “Hepatic glycogenosis: reversible hepatomegaly in type 1 diabetes,” Journal of Paediatrics and Child Health, vol. 36, no. 5, pp. 449–452, 2000. View at: Publisher Site | Google Scholar
  11. M. Silva, M. Marques, H. Cardoso et al., “Glycogenic hepatopathy in young adults: a case series,” Revista Espanola de Enfermedades Digestivas, vol. 108, 2016. View at: Google Scholar
  12. M. Nakamuta, M. Ohashi, K. Goto, Y. Tanabe, K. Hiroshige, and H. Nawata, “Diabetes mellitus- associated glycogen storage hepatomegaly: report of a case and review of the Japanese literature Fukuoka,” Igaku Zasshi, vol. 84, no. 7, pp. 354–358, 1993. View at: Google Scholar
  13. T. Tsujimoto, M. Takano, M. Nishiofuku et al., “Rapid onset of glycogen storage hepatomegaly in a type-2 diabetic patient after a massive dose of long-acting insulin and large doses of glucose,” Internal Medicine, vol. 45, no. 7, pp. 469–473, 2006. View at: Publisher Site | Google Scholar
  14. T. C. Lance, H. Shiloh, and L. Dembo, “Hepatomegaly following short-term high-dose steroid therapy,” Journal of Pediatric Gastroenterology and Nutrition, vol. 5, no. 1, pp. 41–46, 1986. View at: Publisher Site | Google Scholar
  15. J. M. Resnick, I. Zador, and D. L. Fish, “Dumping syndrome, a cause of acquired glycogenic hepatopathy,” Pediatric and Developmental Pathology, vol. 14, no. 4, pp. 318–321, 2011. View at: Publisher Site | Google Scholar
  16. M. C. G. J. Brouwers, J. C. Ham, E. Wisse et al., “Elevated lactic levels in patients with poorly regulated type 1 diabetes and glycogenic hepatopathy: a new feature of Mauriac syndrome,” Diabetes Care, vol. 38, no. 2, pp. e11–e12, 2015. View at: Publisher Site | Google Scholar
  17. H. R. Jeong, Y. S. Shim, Y. B. Kim, H. S. Lee, and J. S. Hwang, “Glycogenic Hepatopathy in a Korean girl with poorly controlled type 1 diabetes mellitus,” Annals of Pediatric Endocrinology & Metabolism, vol. 19, no. 1, pp. 49–52, 2014. View at: Publisher Site | Google Scholar
  18. S. Mukewar, A. Sharma, K. A. Lackore et al., “Clinical, biochemical, and histopathology features of patients with glycogenic hepatopathy,” Clinical Gastroenterology and Hepatology, vol. 15, no. 6, pp. 927–933, 2017. View at: Publisher Site | Google Scholar
  19. J. A. Fridell, R. Saxena, N. P. Chalasani, W. C. Goggins, J. A. Powelson, and O. W. Cummings, “Complete reversal of glycogen hepatopathy with pancreas transplantation: two cases,” Transplantation, vol. 83, no. 1, pp. 84–86, 2007. View at: Publisher Site | Google Scholar
  20. T. Saadi, “Glycogenic hepatopathy: a rare disease that can appear and resolve rapidly in parallel with glycemic control,” Israel Medical Association Journal, vol. 14, no. 4, pp. 269-270, 2012. View at: Google Scholar
  21. J. Khoury, Y. Zohar, N. Shehadeh, and T. Saadi, “Glycogenic hepatopathy,” Hepatobiliary & Pancreatic Diseases International, vol. 17, no. 2, pp. 113–118, 2018. View at: Publisher Site | Google Scholar
  22. J. H. Cha, S. H. Ra, Y. M. Park et al., “Three cases of glycogenic hepatopathy mimicking acute and relapsing hepatitis in type I diabetes mellitus,” Clinical and Molecular Hepatology, vol. 19, no. 4, pp. 421–425, 2013. View at: Publisher Site | Google Scholar
  23. M. T. Julián, N. Alonso, I. Ojanguren et al., “Hepatic glycogenosis: an underdiagnosed complication of diabetes mellitus?” World Journal of Diabetes, vol. 6, no. 2, pp. 321–325, 2015. View at: Publisher Site | Google Scholar
  24. M. Satyarengga, Y. Zubatov, S. Frances, G. Narayanswami, and R. J. Galindo, “Glycogenic hepatopathy: a complication of uncontrolled diabetes,” AACE Clinical Case Reports, vol. 3, no. 3, pp. e255–e259, 2017. View at: Publisher Site | Google Scholar
  25. N. Parmar, M. Atiq, L. Austin, R. A. Miller, T. Smyrk, and K. Ahmed, “Glycogenic hepatopathy: thinking outside the box,” Case Reports in Gastroenterology, vol. 9, no. 2, pp. 221–226, 2015. View at: Publisher Site | Google Scholar
  26. M. Chen, T. Y. Kim, and A. M. Pessegueiro, “Elevated lactate levels in a non-critically ill patient,” JAMA, vol. 313, no. 8, pp. 849-850, 2015. View at: Publisher Site | Google Scholar
  27. F. Murata, I. Horie, T. Ando et al., “A case of glycogenic hepatopathy developed in a patient with new-onset fulminant type 1 diabetes: the role of image modalities in diagnosing hepatic glycogen deposition including gradient-dual-echo MRI,” Endocrine Journal, vol. 59, no. 8, pp. 669–676, 2012. View at: Publisher Site | Google Scholar
  28. A. Chandel, B. Scarpato, J. Camacho, M. McFarland, and S. Mok, “Glycogenic hepatopathy: resolution with minimal glucose control,” Case Reports in Hepatology, vol. 2017, Article ID 7651387, 3 pages, 2017. View at: Publisher Site | Google Scholar
  29. S. Sweetser and R. E. Kraichely, “The bright liver of glycogenic hepatopathy,” Hepatology, vol. 51, no. 2, pp. 711-712, 2010. View at: Publisher Site | Google Scholar
  30. J. L. Doppman, M. Cornblath, A. J. Dwyer, A. J. Adams, M. E. Girton, and J. Sidbury, “Computed tomography of the liver and kidneys in glycogen storage disease,” Journal of Computer Assisted Tomography, vol. 6, no. 1, pp. 67–71, 1982. View at: Publisher Site | Google Scholar
  31. P. R. Biondetti, D. Fiore, and P. C. Muzzio, “Computed tomography of the liver in von Gierkeʼs disease,” Journal of Computer Assisted Tomography, vol. 4, no. 5, pp. 685-686, 1980. View at: Publisher Site | Google Scholar
  32. M. A. Fischer, D. Nanz, C. S. Reiner et al., “Diagnostic performance and accuracy of 3-D spoiled gradient-dual-echo MRI with water- and fat- signal separation in liver-fat quantification: comparison to liver biopsy,” Investigative Radiology, vol. 45, no. 8, pp. 465–470, 2010. View at: Publisher Site | Google Scholar
  33. F. Springer, J. Machann, C. D. Claussen et al., “Liver fat content determined by magnetic resonance imaging and spectroscopy,” World Journal of Gastroenterology, vol. 16, no. 13, pp. 1560–1566, 2010. View at: Publisher Site | Google Scholar
  34. P. Angulo, “Nonalcoholic fatty liver disease,” New England Journal of Medicine, vol. 346, no. 16, pp. 1221–1231, 2002. View at: Publisher Site | Google Scholar
  35. P. Saxena, I. Turner, and R. McIndoe, “Hepatobiliary and pancreatic: glycogenic hepatopathy: a reversible condition,” Journal of Gastroenterology and Hepatology, vol. 25, no. 3, p. 646, 2010. View at: Publisher Site | Google Scholar
  36. K. E. Imtiaz, C. Healy, S. Sharif et al., “Glycogenic hepatopathy in type 1 diabetes: an underrecognized condition,” Diabetes Care, vol. 36, no. 1, pp. e6–e7, 2013. View at: Publisher Site | Google Scholar
  37. J. M. Sherigar, J. D. Castro, Y. M. Yin, D. Guss, and S. R. Mohanty, “Glycogenic hepatopathy: a narrative review,” World Journal of Hepatology, vol. 10, no. 2, pp. 172–185, 2018. View at: Publisher Site | Google Scholar

Copyright © 2020 Atinuke Aluko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

38 Views | 138 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.